Near-infrared (NIR) light, with wavelengths of 650 to 900 nanometers, effectively penetrates tissues. The high signal to noise ratio and low phototoxicity of NIR light makes this wavelength range ideal for deep tissue imaging. However, current NIR fluorophores are generally large hydrophobic molecules that are prone to aggregation. Sulfonation can enhance aqueous solubility, but their anionic nature prevents membrane diffusion, and thus, restricts the applications of sulfonated molecules to in vitro or fixed cells. The repertoire of commercially available sulfonated NIR probes is mostly limited cyanines, which have low photostability. Moreover, larger cyanines require multiple sulfonates to maintain aqueous solubility. For example, Indocyanine Green is only sparingly soluble in PBS, despite having two sulfonates. My work has focused on the delivery of sulfonated dyes into live cells and the development of a new, ultra-compact NIR dye scaffold. First, to expand the in-cell applications of sulfonated fluorophores, I designed reductively-labile sulfonate protecting groups. Using these scaffolds, I have successfully delivered the fluorophore dansyl sulfonate into live cells, where the cytosolic reducing environment unmasks the anionic sulfonate. Secondly, to create a compact, photostable NIR fluorophore, I pioneered the discovery of azasilines dyes. The two azasiline derivatives, ASiFluor710 and ASiFluor730, fluoresce over 700 nanometers and are among the most compact NIR fluorophores currently known. ASiFluor730 also retains the high photostability of oxazine dyes, highlighting their potential in long exposure applications. Beyond the immediate applications in fluorescence microscopy and in vivo imaging, I envision that my work will serve as a framework for the future design of soluble, membrane permeable, NIR fluorescent probes.

The synthetic routes to three types of phosphate prodrugs of 6-hetaryl-7-deazapurine ribonucleosides based on palladium-catalyzed cross-coupling reactions have been developed. CycloSal- and phosphoramidate pronucleotides and octadecyl phosphates derived from 6- hetaryl-7-deazapurine ribonucleosides were screened for their in vitro cytostatic activity. It was shown that cytostatic activity of cycloSal phosphates was similar or slightly lower compared to the parent nucleosides. Significant drop of cytostatic activity was observed in phosphoramidate pronucleotides. Octadecyl phosphates were devoid of any cytostatic activity. 6-Hetaryl-7-deazapurine ribonucleosides with bulky groups in position 6 showed very strong and selective inhibition of adenosine kinase from Mycobacterium tuberculosis. 2'-Modified 6-hetaryl-7-deazapurine nucleosides: 2'-O-methylribonucleosides, arabinonucleosides and 2'- deoxy-2'-fluororibonucleosides, were prepared by multistep functional group transformations from a ribonucleoside. The synthesis of 2'-deoxy-2',2'-difluoro-erythro-pentofuranosyl nucleosides was based on a glycosylation of 6-chloro-7-deazapurine with a sugar synthon followed by palladium-catalyzed cross-coupling reaction and deprotection. Despite the low yields and laborious separation of the anomers,...

La réévaluation des impacts toxicologique et environnemental des répulsifs synthétiques conduit à reconsidérer les répulsifs d'origine naturelle pour la prévention des maladies transmises par les insectes (dengue, chikungunya, paludisme,…). Cette étude se rapporte aux structures de type bis(oxazolidine) envisagées comme prodrogues de répulsifs naturels par leur conversion avec le tris(hydroxyméthyl)aminométhane (TRIS). Différents protocoles et voies de synthèse ont été étudiés sur une série représentative d'aldéhydes pour définir l'étendue et les limites de l'approche permettant de concentrer deux unités d'un même principe actif au sein de bis(oxazolidines) symétriques et de reproduire un effet synergique avec deux unités différentes formant des bis(oxazolidines) dissymétriques. La fonctionnalisation des bis(oxazolidines) a été également envisagée pour moduler leur balance hydrophile-lipophile. L'étude de la réaction de cyclocondensation met en évidence l'influence des paramètres structuraux sur le procédé de synthèse des bis(oxazolidines), la stabilité des intermédiaires (monooxazolidines) et la stéréosélectivité de la réaction. L'interprétation des résultats est proposée sur la base des effets (stéréo)-électroniques. Cette étude démontre l'intérêt de cette approche chimique pour la production de prodrogues de répulsifs naturels qui peuvent constituer des atouts pour le développement durable. / The more sensitive human and environmental risk assessments of non natural repellents have encouraged the rehabilitation of botanical-based repellents for the prevention of insect-transmitted diseases (dengue, chikungunya, malaria…). This study is related to bis(oxazolidine) structures envisaged as prodrug derivatives of natural repellents by their conversion with tris(hydroxymethyl)aminomethane (TRIS). The scope and limitations of various procedures and pathways have been assessed with structurally diverse aldehydes to concentrate two identical units in the symmetrical structures and to reproduce a synergistic effect with two different units in the unsymmetrical ones. Subsequent functionalization of the heterocyclic derivatives has been achieved to modulate their hydrophilic-lipophilic balance. The study of the cyclocondensation reaction shows evidence for the influence of structural effects not only on the chemical process but also on the relative stability of the monocyclic intermediates and the stereochemical outcomes of the reaction. The results are discussed on the basis of (stereo)-electronic effects. Finally, this study confirms the feasibility of this chemical approach to produce prodrugs of natural repellents which could appear as a contributive effort to sustainable development.

Le travail suivant est consacré d'une part à l'emploi du calix[4]arène comme une plate-forme organisatrice de principes actifs pour la conception de nouvelles prodrogues. Ce concept a été développé avec des substances antibactériennes ou antivirales, choisies comme modèles. Les conjugués calixarène - anti-infectieux ainsi synthétisés sont amphiphiles et insolubles dans l'eau. Leur comportement interfacial a été étudié via l'interface eau-air, mime d'une interface hydrophile-hydrophobe physiologique, à l'aide de la technique des films monomoléculaires de Langmuir. Nos résultats indiquent que ces prodrogues étalées à l'interface eau-air peuvent libérer leurs principes actifs dans la sous-phase. La méthodologie développée pour ces études de réactivité interfaciale pourrait à l'avenir être appliquée à d'autres prodrogues à base de calix[4]arène. Un second projet a concerné le trifluoroacétate de tétra-p-(guanidinoéthyl)-calix[4]arène (CX1). Ce composé présente des propriétés antibactériennes à large spectre, couplées à une faible toxicité cellulaire. Nos travaux ont visé à mieux comprendre son mode d'action, lié à une perturbation des parois bactériennes, par une approche physico-chimique. La technique de Langmuir a donc été employée afin d'étudier les interactions entre le CX1 et des films monomoléculaires de phospholipides étalés à l'interface eau-air, utilisés comme modèles de membrane bactérienne. Nos résultats nous ont permis de proposer un mode d'organisation des membranes bactériennes sous l'influence du CX1. Nous avons ainsi apporté des précisions sur son mécanisme d'action qui pourraient être utiles dans le développement de nouveaux calixarènes antibactériens / This work begins with utilization of the calix[4]arene macrocycle as organizing platform of anti-infectious molecules shaped as prodrug. The concept has been explored using antibacterial (nalidixic acid) and antiviral (aciclovir, ganciclovir) molecules, chosen as models. The calixarene - anti-infectious conjugates synthesized have amphiphilic structure and are insoluble in aqueous media. Their interfacial behavior was studied via the air-water interface, considered as mimic of biological hydrophilic-hydrophobic interfaces, using Langmuir monolayers technique. Our results indicate that calixarene-based prodrugs spread at the air-water interface are able to release anti-infectious molecules into the subphase. The original methodology employed for interfacial reactivity studies could be applied to further calixarene-based prodrugs. A second project concerns the trifluoroacetate salt of tetra-p-(guanidinoethyl)-calix[4]arene (CX1). CX1 is antibacterial, active against various Gram-positive and Gram-negative bacteria, with low eukaryotic cell toxicity. The aim of our work was to get more insight in the mechanism of action of CX1, involving bacterial wall disruption, by a physico-chemical approach. The Langmuir monolayers technique was employed in order to study interactions between CX1 and phospholipid monolayers spread at the air-water interface, used as models of bacterial membranes. Our results led us to propose a particular reorganization mode of bacterial membranes upon interactions with CX1. This proposal gives more understanding in the mechanism of biological activity of CX1, and could be helpful in developing new antibacterial calixarene derivatives

4, 4'-Dihydroxybenzophenone-2, 4-dinitrophenylhydrazone (A-007) has recently completed a phase-I clinical trial, and objective responses were seen in advanced breast cancer, lung cancer, ovarian cancer, melanoma, skin cancer and non-Hodgkin's lymphoma. Despite the promising results in the clinical trials, the major disadvantage to using A-007 as a broad-scale therapeutic is its poor water solubility. To make use of this promising anticancer drug either orally or intravenously, the short-term obstacle must be to overcome the limited solubility of A-007 in water. There are several approaches to overcome this obstacle. The first approach is to make hydrolysable prodrugs of A-007. The second approach is to make an A-007 complex with a water soluble host, such as cyclodextrin. We used a combination of these two previously described methods, i.e. transforming A-007 into a more water soluble prodrugs and then further increasing the prodrug water solubility by making their cyclodextrin inclusion complexes. Our syntheses and spectroscopic explorations of A-007 prodrugs are presented in this dissertation. Tetramic acid (2, 4 pyrrolidine-2, 4-dione ring system) containing compounds have been found to display a remarkable diversity of biological activities and have attracted the interest of medicinal and synthetic chemists. Magnesidin (1-acetyl-3-octanoyl-5-ethylidene tetramic acid) has strong antimicrobial activity against bacteria that cause gingivitis and dental plaque. Current efforts toward the synthesis of Magnesidin are discussed along with the plans for the completion of synthesis.

Biliary excretion is an important elimination route for many drugs and metabolites. For such compounds, it is important to know the extent of excretion and drug exposure in the bile, e.g., for the risk assessment of drug interactions, liver toxicity and the effects of genetic variants. In this thesis, duodenal aspiration of bile was performed in healthy volunteers and complemented with experiments in an in vivo model in pigs to increase the understanding of the intestinal and hepatobiliary disposition of two direct thrombin inhibitors. The compounds investigated, ximelagatran and AZD0837, are both prodrugs that require bioactivation to exert their pharmacological effect. Upon co-administration with erythromycin and ketoconazole, respectively, altered plasma exposure to ximelagatran and AZD0837 and their respective metabolites has been observed. The main objective of this thesis was to characterize the biliary excretion of the compounds, and investigate whether this elimination route explains the observed drug-drug interactions. High plasma-to-bile AUC ratios were observed, in particular for ximelagatran, its active metabolite melagatran, and AR-H067637, the active metabolite of AZD0837. These high ratios indicate the involvement of active transporters in the biliary excretion of the compounds, which is important since transporters constitute possible sites for drug interactions. The effects of erythromycin and ketoconazole on the plasma exposure of the prodrugs and metabolites were confirmed in both the pig and the clinical studies. The changes seen in plasma for ximelagatran and its metabolites were partly explained by reduced biliary clearance. Inhibited CYP3A4 metabolism likely caused the elevated plasma levels of AZD0837, whereas reduced biliary clearance was seen for AR-H067637 suggesting an effect on its excretion into bile. In summary, the studies led to mechanistic insights in the hepatobiliary disposition of ximelagatran and AZD0837, and demonstrate the value of combined clinical and animal studies for the investigation of the biliary drug excretion.

Les cibles épigénétiques telles que les histones désacétylases (HDAC) sont étudiées comme nouveaux traitements anticancéreux, leur fonctionnement anormal étant associée aux processus cancéreux. De nombreux inhibiteurs de ces enzymes sont apparus tel que le SAHA ou le CI-994. Notre laboratoire a développé un nouvel analogue de la trichostatine A appelé NODH. Malgré leur activité anticancéreuse in vitro prometteuse, ces inhibiteurs souffrent de leur manque de solubilité, d'effets toxiques et de leur rapide métabolisation par l'organisme. Afin de pallier ces limitations, ces iHDAC peuvent être conjugués à des vecteurs capables de les transporter dans l'organisme et de les libérer une fois la cible tumorale atteinte. Ce travail de thèse a consisté dans un premier temps à développer des prodrogues acido-sensibles capable de libérer la substance active après endocytose par les cellules. Ces systèmes ont été appliqués aux trois iHDAC SAHA, CI-994 et NODH. Les prodrogues développées ont ensuite été accrochées sur des nanoparticules polymériques connues pour leur biocompatibilité et leur accumulation dans les tumeurs grâce à l'effet EPR. L'activité anticancéreuse de certaines nanoparticules a été validée par des tests in vitro et in vivo. Un deuxième travail a été entrepris concernant la préparation de prodrogues fluorescentes pH labiles capables de libérer la substance active et de moduler la fluorescence par la variation du pH. La dernière partie de ce travail a été consacrée à la mise au point d'une nouvelle méthode de synthèse par voie superacide potentiellement stéréosélective de benzofuranones nécessaires à la préparation d'analogues de NODH. / Epigenetic targets like histone deacetylases (HDAC) are studied as new anticancer treatments, their dysfunctioning being associated to cancer mechanisms. Several epigenetic target inhibitors have been developed like SAHA or CI-994. Our group has developed a new trichostatin A analogue called NODH. Despite their promising in vitro anticancer effect, these inhibitors suffer from lack of solubility, toxic effects and rapid clearance. These constrains make the HDACi good candidates for ligation to vectors able to carry them in the body and to release them when the tumor is reached. The first part of this thesis work has focused on the development of acid sensitive prodrugs able to release an active substance after cellular internalization by endocytosis. These systems were applied to three HDACi SAHA, CI-994 and NODH. These prodrugs were then conjugated to polymeric nanoparticles known for their biocompatibility and their accumulation in tumors exploiting the EPR effect. The anticancer activity of some nanoparticles has been validated by in vitro and in vivo tests. The second part of this work was carried out in order to prepare pH sensitive fluorescent prodrugs able to release the active molecule and to modulate the fluorescent effect by pH changes. The last part of this work was dedicated for the development of a new synthesis in suparacid potentially stereoselective of several benzofuranones required for the preparation of NODH analogs.

Cancer cell esterases are often overexpressed and can have chiral specificities different from that of the corresponding normal cells and can, therefore, be useful targets for activating chemotherapeutic prodrug esters. Prodrug esters are inactive compounds that can be preferentially activated by esterase enzymes. Moreover, cancer cells often exhibit a high level of intrinsic oxidative stress due to an increased formation of reactive oxygen species (ROS) and a decreased expression of some enzymatic antioxidants. Prodrugs designed to induce additional oxidative stress can selectively induce apoptosis in cancer cells already exhibiting a high level of intrinsic oxidative stress. This study focused on the in vitro evaluation of four novel prodrug esters: the R- and S- chiral esters of 4-[(nitrooxy)methyl]phenyl N-acetylalaninate (R- and S-NPAA) and the R- and S- chiral esters of 4-[(nitrooxy)methyl]naphth-1-yl N-acetylalaninate (R- and S-NQM), which are activated, to varying extents, by oxidized protein hydrolase (OPH, EC 3.4.19.1) yielding a quinone methide (QM) intermediate capable of depleting glutathione (GSH), a key intracellular antioxidant. OPH is a serine esterase/protease that is overexpressed in some human tumors and cancer cell lines.Methods: To evaluate the chiral ester prodrugs, we monitored cellular GSH depletion, cellular protein carbonyl levels (an oxidative stress biomarker) and cell viability in tumorigenic and nontumorigenic prostate cancer cell lines.Results: We found that the prodrugs were activated by OPH and subsequently depleted GSH. The S-chiral ester of NPAA (S-NPAA) was two-fold more effective than the R-chiral ester (R-NPAA) in depleting GSH, increasing oxidative stress, inducing apoptosis, and decreasing cell viability in tumorigenic prostate LNCaP cells but had little effect on non-tumorigenic RWPE-1 cells. In addition, we found that that S-NPAA induced apoptosis and decreased cell viability in tumorigenic DU145 and PC3 prostate cell lines. Similar results were found in a COS-7 model that overexpressed active human OPH (COS-7-OPH).Conclusions: Our results suggest that prostate tumors overexpressing OPH and/or exhibiting a high level of intrinsic oxidative stress may be susceptible to QM generating prodrug esters that are targeted to OPH with little effect on non-tumorigenic prostate cells.

<p>Therapeutic peptides have become a clinically and commercially important drug class providing novel treatment options in variety of disease areas. Today, more than 80 peptide drugs are marketed worldwide and hundreds more are in development. However, the development of peptide drugs can be hindered by their tendency to self-associate to form fibrils, an impurity that can affect potency and increase the potential for adverse immune responses in patients. Fibrillation of therapeutic peptides can present significant quality concerns and poses challenges for manufacturing and storage. From a pharmaceutical development perspective, early detection of instabilities can inform the development of mitigation strategies to minimize the risk of product failure and avoid costly delays in clinical development. A fundamental understanding of the mechanisms of fibrillation is critical for the rational design of fibrillation-resistant peptide drugs and formulations.</p> <p>The objective of this dissertation was to develop structurally modified fibrillation-resistant peptides based on a mechanistic understanding of the fibrillation process. The therapeutic peptides studied were human calcitonin (hCT), a glucagon/GLP-1 analog, and human insulin B-chain (INSB). Pulsed hydrogen-deuterium exchange mass spectrometry (HDX-MS) and other biophysical methods were used to provide mechanistic understanding of the intermolecular interactions and structural transitions during peptide fibrillation. Coupled with proteolytic digestion, pulsed HDX-MS of fibrillating peptides enabled identification of the residues involved in the early interactions leading to fibrillation based on their differential deuterium exchange rates. The high-resolution residue level information was used to make site-specific modifications to hCT, with phosphorylation in the central region resulting in complete inhibition of fibrillation for the phospho-Thr-13 hCT analog under the stress conditions employed. Reversible ‘prodrug’ modifications such as phosphorylation can aid the rational design of fibrillation-resistant therapeutic peptides. Furthermore, the effects of structural modifications on peptide fibrillation were evaluated by reducing the Cys1-Cys7 disulfide bond in hCT, and by C-terminal amidation or substitution with a helix-stabilizing residue (α-aminoisobutyric acid, Aib) in the glucagon/GLP-1 analog peptide. Finally, studies of insulin B-chain probed fibrillation mechanisms of this therapeutically important peptide, contributing to our understanding of the mechanisms of insulin fibrillation with the broad goal of developing fibrillation-resistant, rapid-acting, monomeric insulin analogs. Overall, the results demonstrate that small structural changes can have significant effects on peptide fibrillation, that pulsed HDX-MS can be used to probe these effects, and that an understanding of these effects can inform the rational development of fibrillation-resistant peptide drugs. </p>

Les précédents travaux menés au laboratoire avaient permis d’obtenir des lipides cationiques biolabiles dérivés d’un constituant naturel des membranes cellulaires, la DOPC, en masquant temporairement sa charge négative par l’introduction d’un substituant, clivable sous stimuli acide ou enzymatique. Ce concept s’était révélé efficace pour la délivrance, in vitro et in vivo, d’acides nucléiques, avec un impact toxicologique minimisé. Ce doctorat est la transposition de ce système à une approche thérapeutique du cancer, à l’aide de constructions dérivées d’alkylphospholipides (APLs), des lipides antitumoraux. De nombreuses prodrogues biolabiles (pro-APLs) ont été développées à partir de trois APLs prometteurs : miltéfosine, périfosine et érufosine. L’évaluation et l’optimisation de l’activité biologique des pro-APLs ont conduit à des formulations performantes pour la délivrance in vitro d’un ADN thérapeutique TRAIL et la production in situ d’APLs, pour une combothérapie antitumorale. / Previous work in the laboratory had resulted in biolabile cationic lipids derived from a naturally cell membrane component, DOPC, by temporarily masking its negative charge by the introduction of a cleavable substituent, under acidic or enzymatic stimuli. This concept was particularly efficient for the delivery, in vitro and in vivo, of nucleic acids such as DNA plasmid or siRNA, with a minimized toxicological impact for cells. The present study is the transposition of this system to a therapeutic approach to cancer, using constructions derived from alkylphospholipids (APLs), a recent class of antitumor lipids. Biolabile prodrugs (pro-APLs) have been developed from three promising APLs: miltefosine, perifosine and erufosine. The biological evaluation of pro-APLs activity and the optimization of various parameters led to efficient formulations for the in vitro delivery of a therapeutic DNA plasmid, related to TRAIL, and the in situ APLs production for a potential antitumor combotherapy.